Hege Marie Vedeld

  • Post.doc.; PhD
  • +47 2278 1747

Main project: Epigenetic predisposition for cancer - Identification of epigenetic changes in early onset colorectal cancer patients.

 

Academic degrees:

2011: MSc, The Faculty of Mathematics and Natural Sciences, University of Oslo. Thesis: 'DNA methylation biomarkers for colorectal cancer detection: CDO1, DCLK1, ZNF331 and ZSCAN18'

 

Publications 2019

Marcuello M, Vymetalkova V, Neves RPL, Duran-Sanchon S, Vedeld HM, Tham E, van Dalum G, Flügen G, Garcia-Barberan V, Fijneman RJ, Castells A, Vodicka P, Lind GE, Stoecklein NH, Heitzer E, Gironella M (2019)
Circulating biomarkers for early detection and clinical management of colorectal cancer
Mol Aspects Med, 69, 107-122
DOI 10.1016/j.mam.2019.06.002, PubMed 31189073

Publications 2018

Pinto D, Pinto C, Guerra J, Pinheiro M, Santos R, Vedeld HM, Yohannes Z, Peixoto A, Santos C, Pinto P, Lopes P, Lothe R, Lind GE, Henrique R, Teixeira MR (2018)
Contribution of MLH1 constitutional methylation for Lynch syndrome diagnosis in patients with tumor MLH1 downregulation
Cancer Med, 7 (2), 433-444
DOI 10.1002/cam4.1285, PubMed 29341452

Vedeld HM, Nesbakken A, Lothe RA, Lind GE (2018)
Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer
Clin Epigenetics, 10, 70
DOI 10.1186/s13148-018-0503-2, PubMed 29854011

Publications 2017

Vedeld HM, Goel A, Lind GE (2017)
Epigenetic biomarkers in gastrointestinal cancers: The current state and clinical perspectives
Semin Cancer Biol, 51, 36-49
DOI 10.1016/j.semcancer.2017.12.004, PubMed 29253542

Vedeld HM, Merok M, Jeanmougin M, Danielsen SA, Honne H, Presthus GK, Svindland A, Sjo OH, Hektoen M, Eknaes M, Nesbakken A, Lothe RA, Lind GE (2017)
CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers
Int J Cancer, 141 (5), 967-976
DOI 10.1002/ijc.30796, PubMed 28542846

Publications 2016

Pharo HD, Honne H, Vedeld HM, Dahl C, Andresen K, Liestøl K, Jeanmougin M, Guldberg P, Lind GE (2016)
Experimental factors affecting the robustness of DNA methylation analysis
Sci Rep, 6, 33936
DOI 10.1038/srep33936, PubMed 27671843

Publications 2015

Andresen K, Boberg KM, Vedeld HM, Honne H, Jebsen P, Hektoen M, Wadsworth CA, Clausen OP, Lundin KE, Paulsen V, Foss A, Mathisen Ø, Aabakken L, Schrumpf E, Lothe RA, Lind GE (2015)
Four DNA methylation biomarkers in biliary brush samples accurately identify the presence of cholangiocarcinoma
Hepatology, 61 (5), 1651-9
DOI 10.1002/hep.27707, PubMed 25644509

Publications 2014

Vedeld HM, Andresen K, Eilertsen IA, Nesbakken A, Seruca R, Gladhaug IP, Thiis-Evensen E, Rognum TO, Boberg KM, Lind GE (2014)
The novel colorectal cancer biomarkers CDO1, ZSCAN18 and ZNF331 are frequently methylated across gastrointestinal cancers
Int J Cancer, 136 (4), 844-53
DOI 10.1002/ijc.29039, PubMed 24948044

Vedeld HM, Skotheim RI, Lothe RA, Lind GE (2014)
The recently suggested intestinal cancer stem cell marker DCLK1 is an epigenetic biomarker for colorectal cancer
Epigenetics, 9 (3), 346-50
DOI 10.4161/epi.27582, PubMed 24384857

Publications 2012

Andresen K, Boberg KM, Vedeld HM, Honne H, Hektoen M, Wadsworth CA, Clausen OP, Karlsen TH, Foss A, Mathisen O, Schrumpf E, Lothe RA, Lind GE (2012)
Novel target genes and a valid biomarker panel identified for cholangiocarcinoma
Epigenetics, 7 (11), 1249-57
DOI 10.4161/epi.22191, PubMed 22983262

Page visits: 5673